
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
The company that spun out Karuna is cashing in on a $500 million deal with Royalty Pharma, just days after the biotech rolled out positive late-stage data and a nine-figure raise.
PureTech Health announced Thursday that Royalty Pharma, the company helmed by Pablo Legorreta that buys royalty streams, got its hands on part of PureTech’s royalty in Karuna Therapeutics’ schizophrenia candidate KarXT, which combines former Eli Lilly candidate xanomeline with trospium.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.